Analyst Steve Burrill says the biotech IPO market is coming back! (Check out my biotech blog for more on this.)
But Burrill says this in Reuters:
"In addition to the long-awaited reopening of the IPO window, it's likely that the final quarter of the year will bring yet more product approvals, more successes in the clinic and more proof of concept ... all of which will infuse even greater value into the industry."
Word also is that a bunch of FDA drug approvals are scheduled for later this fall. All in all, great news for the sector!